Key Highlights

  • Up 9.32 percent to USD 0.7980 in pre-market trading on November 2, 2026.
  • Nasdaq sent a minimum bid price notice on October 23, 2026.
  • The compliance deadline is April 21, 2027.
  • Q2 2026 product Revenue was USD 559 thousand, with a net loss of USD 28.6 million.
  • Cash and investments were USD 170.6 million at June 30, 2026.

What Moved Milestone Shares Pre-Market

Milestone Pharmaceuticals (NASDAQ:MIST) was up 9.32 percent to USD 0.7980 in pre-market trading on November 2, 2026. No company announcement dated November 2, 2026 was identified.

The shares remain below USD 1.00, and the move looks like a bounce in a heavily sold, low-priced biotech name rather than a response to new company disclosure.

The Nasdaq Bid Price Notice

According to a regulatory filing dated October 28, 2026, the company received a Nasdaq notice on October 23, 2026 under Listing Rule 5450(a)(1) because its shares closed below the USD 1.00 minimum bid price. The company has 180 calendar days, through April 21, 2027, to regain compliance by closing at or above USD 1.00 for at least 10 consecutive Business days.

The notice does not immediately affect the Global Select Market listing. The company may consider transferring to the Nasdaq Capital Market or a reverse stock split, though neither has been announced.

Business Background And Recent Results

Milestone is a commercial-stage biopharmaceutical company focused on cardiovascular medicines. Its product CARDAMYST, a nasal spray for paroxysmal supraventricular tachycardia, launched in mid-February 2026.

In its second-quarter release dated August 12, 2026, the company reported product revenue of USD 559 thousand and a net loss of USD 28.6 million, or USD 0.21 per share. Selling, general and administrative expenses rose to USD 22.6 million from USD 8.9 million on launch costs. Over 800 prescribers had started patients by June 30, 2026, and commercial coverage had grown to about 50 percent of lives.

Balance Sheet And Risks

The company reported USD 170.6 million in cash, cash equivalents and short-term investments at June 30, 2026, and said this should fund operations into the second half of 2027. Spending is rising faster than revenue, so future financing and dilution remain possible.

As a penny stock, the shares can be volatile and thinly traded in extended hours.

What To Watch Next

Key items include third-quarter results, further CARDAMYST prescription data and any decision on a reverse split or market transfer. The company also said a European regulatory decision is expected in the first half of 2027 and that first patient enrollment in its Phase 3 atrial fibrillation trial is planned for the second half of 2026.

Trading on November 2, 2026 will show whether the pre-market bounce holds.